Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.20), $0.09 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $23.53 million versus the consensus estimate of $21.74 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.